Michelle Cortez

The speaker explicitly listed CVS among the "big insurance companies" benefiting from the Medicare Advantage rate decision. CVS (via its Aetna business) is a significant participant in the Medicare Advantage market. The better-than-feared rate hike removes a major overhang on the profitability of this segment. LONG because the company is identified as a winner from the policy reversal, which should support its integrated health services model. Similar to peers, the long-term risk is regulatory pressure to reduce costs within the Medicare Advantage program.

The speaker explicitly stated "Humana is benefiting" following the announcement of the improved Medicare Advantage rate hike. Humana, as a major player in Medicare Advantage, faced significant downside risk from a 0% rate increase. The final 2.48% hike alleviates that pressure and improves the earnings outlook. LONG as the company is named a direct beneficiary of the positive regulatory development, which supports its core business model. The company's heavy exposure to Medicare Advantage makes it vulnerable to any future regulatory attempts to curtail payment growth more severely.

The speaker explicitly stated UnitedHealth's stock was "going through the roof today" following the announcement of a 2.48% Medicare Advantage rate increase for 2027. The final rate was much better than the 0% initially feared, representing a positive expectation shock. Companies that remained in the Medicare Advantage market are positioned to benefit. LONG because the company is a direct, immediate beneficiary of the favorable rate decision, which secures its profitability in a key business line for the near term. Future administration policy aimed at aggressively dialing back program costs could pressure margins and lead to strategic pullbacks.